Related Experiment Video

Updated: Jun 28, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

Targeting the Cdc2-like kinase 2 for overcoming platinum resistance in ovarian cancer

Yinan Jiang1, Shuting Huang2, Lan Zhang3

  • 1Department of Gynecology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou China.

Medcomm
|April 15, 2024
PubMed

Insights

Cdc2-like kinase 2 (CLK2) promotes platinum resistance in ovarian cancer (OC) by enhancing DNA repair. Targeting CLK2 offers a potential strategy to overcome resistance, particularly in patients with wild-type BRCA1.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Platinum resistance is a significant challenge in ovarian cancer (OC) treatment.
  • The role of Cdc2-like kinase 2 (CLK2) in OC progression and platinum resistance is not well understood.

Purpose of the Study:

  • To investigate the role and mechanism of CLK2 in ovarian cancer progression and platinum resistance.
  • To explore CLK2 as a potential therapeutic target for overcoming platinum resistance in OC.

Main Methods:

  • Microarray gene expression profiling and immunostaining of OC tissues.
  • In vitro functional assays on OC cells and in vivo studies using tumor xenografts.
  • Analysis of CLK2 phosphorylation by p38 and its effect on breast cancer gene 1 (BRCA1).

Main Results:

  • CLK2 was upregulated in OC tissues and correlated with shorter platinum-free intervals.
  • CLK2 overexpression conferred resistance to platinum-induced apoptosis and reduced treatment efficacy in xenografts.
  • CLK2 phosphorylated BRCA1 at Ser1423, enhancing DNA damage repair and leading to platinum resistance.
  • p38 kinase stabilized CLK2 protein in platinum-treated OC cells.
  • Combination therapy with CLK2 and poly (ADP-ribose) polymerase inhibitors showed synergistic lethality, especially in wild-type BRCA1 tumors.

Conclusions:

  • CLK2 plays a crucial role in promoting platinum resistance in ovarian cancer through enhanced DNA repair.
  • Targeting CLK2, in combination with PARP inhibitors, presents a promising strategy to overcome platinum resistance in OC, particularly in BRCA1-wildtype settings.
Keywords:
Cdc2‐like kinase 2DNA damage repairovarian cancerplatinum resistancesynergistic lethal

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K